Abstract

Pfizer has agreed to acquire the antiviral therapy developer ReViral for up to $525 million, plus possible milestone payments. The British firm’s lead product is sisunatovir, a small molecule that targets the respiratory syncytial virus and is in Phase 2 clinical studies. ReViral was cofounded a decade ago by Stuart Cockerill, an organic chemist who earlier invented the GlaxoSmithKline cancer treatment Tykerb.

Full Text
Paper version not known

Talk to us

Join us for a 30 min session where you can share your feedback and ask us any queries you have

Schedule a call